Facts for Prelims (FFP)
Source: PIB
Context: Scientists from the Department of Atomic Energy (DAE) and M/s. IDRS Labs Pvt. Ltd. in Bengaluru have collaboratively developed a breakthrough nutraceutical named AKTOCYTE tablets.
- These tablets aim to enhance the quality of life for cancer patients undergoing radiotherapy by minimizing the side effects associated with the treatment.
- AKTOCYTE tablets have shown remarkable results, particularly in pelvic cancer patients undergoing radiotherapy-induced Cystitis, leading to extraordinary recovery and eliminating the need for surgical interventions like the removal of the urinary bladder.
- The tablets, designed as an adjuvant to cancer radiotherapy, act as a regenerative nutraceutical, immunomodulator, and antioxidant, representing a significant advancement in cancer care.
- AKTOCYTE has received approval from the Food Safety and Standards Authority of India (FSSAI), ensuring its safety and compliance with quality standards
